{"id":77542,"date":"2024-03-12T13:58:29","date_gmt":"2024-03-12T18:58:29","guid":{"rendered":"https:\/\/equitynewsreport.com\/aslan-pharmaceuticals-announces-5-million-offering\/"},"modified":"2024-03-12T13:58:29","modified_gmt":"2024-03-12T18:58:29","slug":"aslan-pharmaceuticals-announces-5-million-offering","status":"publish","type":"post","link":"https:\/\/equitynewsreport.com\/h\/aslan-pharmaceuticals-announces-5-million-offering\/","title":{"rendered":"ASLAN Pharmaceuticals announces $5 million offering"},"content":{"rendered":"<div readability=\"77\">\n<div id=\"imgCarousel\" class=\"imgCarousel\">\n<img decoding=\"async\" alt=\"ASLAN Pharmaceuticals announces $5 million offering\" id=\"carouselImage\" src=\"https:\/\/i-invdn-com.investing.com\/news\/LYNXNPEC3B0CQ_L.jpg\"><br \/>\n<span class=\"text\">\u00a9 Reuters. <\/span><br \/>\n<i class=\"imgGrad\"><\/i>\n<\/div>\n<p>SAN MATEO, Calif. and SINGAPORE &#8211; ASLAN Pharmaceuticals Ltd. (NASDAQ:ASLN), a biopharmaceutical company specializing in immunology, has announced a registered direct offering and concurrent private placement of securities intended to raise $5 million in gross proceeds.<\/p>\n<p>The company plans to sell 5 million American Depositary Shares (ADSs) at $1.00 each. Simultaneously, it will issue warrants to purchase an equal number of ADSs, also at $1.00 per ADS, exercisable immediately and expiring in five years.<\/p>\n<p>The closing of the offering is scheduled for around March 14, 2024, subject to standard closing conditions. H.C. Wainwright &#038; Co. is the exclusive placement agent for the transaction. The net proceeds from the offering will go towards funding research and development activities, working capital, and other general corporate expenses.<\/p>\n<p>ASLAN&#8217;s ADSs are being offered under a shelf registration statement declared effective by the Securities and Exchange Commission (SEC) on April 6, 2023. The warrants and the ADSs underlying them, however, are issued in a private placement and are not registered under the Securities Act or state securities laws, thus they cannot be sold in the U.S. without registration or an exemption.<\/p>\n<p>The company is currently developing eblasakimab, a potential first-in-class antibody for treating moderate-to-severe atopic dermatitis, and farudodstat, a potential first-in-class treatment for alopecia areata, with interim trial results expected in mid-2024.<\/p>\n<p>This financial move comes as part of ASLAN&#8217;s strategy to advance its clinical programs and support its growth initiatives. The information disclosed in this report is based on a press release statement from ASLAN Pharmaceuticals.<\/p>\n<p><em>This article was generated with the support of AI and reviewed by an editor. For more information see our T&#038;C.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00a9 Reuters. SAN MATEO, Calif. and SINGAPORE &#8211; ASLAN Pharmaceuticals Ltd. (NASDAQ:ASLN), a biopharmaceutical company specializing in immunology, has announced a registered direct offering and concurrent private placement of securities intended to raise $5 million in gross proceeds. The company plans to sell 5 million American Depositary Shares (ADSs) at $1.00 each. Simultaneously, it will issue warrants to purchase an equal number of ADSs, also at $1.00 per ADS, exercisable immediately and expiring in five years. The closing of the offering is scheduled for around March 14, 2024, subject to standard closing conditions. H.C. Wainwright &#038; Co. is the exclusive [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":77543,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[49,50,48,3],"tags":[],"_links":{"self":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77542"}],"collection":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/comments?post=77542"}],"version-history":[{"count":0,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77542\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media\/77543"}],"wp:attachment":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media?parent=77542"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/categories?post=77542"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/tags?post=77542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}